Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806

Abstract

Metadata

Authors/Creators:
  • Cortes, J
  • Hudgens, S
  • Twelves, C
  • Perez, EA
  • Awada, A
  • Yelle, L
  • McCutcheon, S
  • Kaufman, PA
  • Forsythe, A
  • Velikova, G
Copyright, Publisher and Additional Information: © The Author(s) 2015. This article is published with open access at Springerlink.com
Keywords: Breast cancer; Eribulin; Quality of life; Minimally important difference; Side effects
Dates:
  • Published: December 2015
  • Accepted: 3 November 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 30 Nov 2015 10:06
Last Modified: 30 Nov 2015 10:06
Published Version: http://dx.doi.org/10.1007/s10549-015-3633-7
Status: Published
Publisher: Springer
Identification Number: https://doi.org/10.1007/s10549-015-3633-7
Related URLs:

Share / Export

Statistics